Lichenoid graft‐versus‐host disease shows a high interferon score, with <scp>IFNAR1</scp> inhibition preventing skin inflammation
Together, our data suggests that interferon pathways, and in particular Type I via IFNAR1, may be promising therapeutic targets for the treatment of lichenoid chronic GVHD.
Authors
- Adèle de Masson (ORCID: https://orcid.org/0000-0001-7828-6211)
- A. Calugareanu (ORCID: https://orcid.org/0000-0003-2841-1680)
- Marie Robin (ORCID: https://orcid.org/0000-0003-1388-9876)
- Flore Sicre de Fontbrune
- Thomas Poisot
- David Michonneau (ORCID: https://orcid.org/0000-0003-4553-3065)
- Hélène Le Buanec (ORCID: https://orcid.org/0000-0002-2139-0357)
- Chloé Grolleau (ORCID: https://orcid.org/0000-0002-8393-7442)
- Régis Peffault de Latour (ORCID: https://orcid.org/0000-0001-6222-4753)
- Jean‐David Bouaziz (ORCID: https://orcid.org/0000-0002-4993-2461)
- Gérard Socié (ORCID: https://orcid.org/0000-0003-3819-8641)
- Maxime Battistella
Institutions
- Inserm (FR)
- Université Paris Cité (FR)
- Assistance Publique – Hôpitaux de Paris (FR)
- Hôpital Saint-Louis (FR)
- Institut de recherche Saint-Louis (FR)
Publication Details
- Journal
- Journal of the European Academy of Dermatology and Venereology
- Published
- 2025-05-29
- DOI
- https://doi.org/10.1111/jdv.20760
- Citations
- 5
- Primary Topic
- Hematopoietic Stem Cell Transplantation
- Type
- article
- Field-Weighted Citation Impact
- 8.85
Funders
- Pfizer
- AstraZeneca
- Société Française de Dermatologie et de Pathologie Sexuellement Transmissible